| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4437 | BI-4464 | 1227948-02-8 | BI-4464 is a novel, potent and highly selective ATP competitive inhibitor ofPTK2/FAKwith anIC50of 17 nM. |
|
V69726 | FAK inhibitor 2 | 2354405-14-2 | FAK inhibitor 2 is a potent focal adhesion kinase (FAK) inhibitor (antagonist) with IC50 of 0.07 nM and has anti-tumor and anti-angiogenic activities. |
|
V85852 | FAK-IN-17 | ||
|
V69720 | FC-11 | 2271035-37-9 | FC-11 is a PROTAC FAK degrader (DC90: 1 nM). |
|
V2836 | GSK2256098 | 1224887-10-8 | GSK2256098 is a small molecule developed by GlaxoSmithKline) as a selective FAK (Focal Adhesion Kinase) kinase inhibitor to inhibit FAK activity through targeting the phosphorylation site of FAK, tyrosine (Y) 397. |
|
V0656 | PF-00562271 besylate | 939791-38-5 | PF-00562271 besylate (also called PF562271 or PF-562271 Besylate), the benzenesulfonate salt form of PF-00562271, is an ATP-competitive and orally bioavailable inhibitor of FAK (focal adhesion kinase) and Pyk2 catalytic activity with potential antitumor activity. |
|
V0661 | PF-431396 | 717906-29-1 | PF-431396 (PF431396) is a pyrimidine-based and selectivedual inhibitor of PYK2 and FAK (focal adhesion kinase and proline-rich tyrosine kinase 2) with potential anti-osteoporoticactivity. |
|
V2696 | PF-562271 | 717907-75-0 | PF-562271 is a novel, potent, ATP-competitive, orally bioavailable, reversible inhibitor of FAK (focal adhesion kinase) and Pyk2 catalytic activity with a IC50 of 1.5 and 14 nmol/L, respectively. |
|
V0660 | PF-562271 HCl | 939791-41-0 | PF-562271 HCl is the hydrochloride salt of PF-562271 (PF562271 or PF 562271), which is a potent, ATP-competitive, orally bioavailable, reversible inhibitor of FAK (focal adhesion kinase) and Pyk2 (proline-rich tyrosine kinase) catalytic activity with potential anticancer activity. |
|
V0658 | PF-573228 | 869288-64-2 | PF-573228 (PF573228) is a selective andATP-competitive FAK (focal adhesion kinase) inhibitorwith potential antitumor activity. |
|
V0662 | PND-1186 (VS-4718; SR-2156) | 1061353-68-1 | PND-1186 (also known as SR2156, PND1186 or VS4718) is a novel, potent, reversible and selective FAK (focal adhesion kinase) inhibitor with potential anticancer activities. |
|
V0659 | TAE226 (NVP-TAE226) | 761437-28-9 | TAE226 (also known as NVP-TAE226; TAE-226) is a novel, potent, selective and ATP competitive small molecule FAK(focal adhesion kinase) inhibitor with potential antineoplastic activity. |
|
V28341 | Y11 | 1086639-59-9 | Y11 (Y-11) is a novel and potent small molecule inhibitor of FAK (focal adhesion kinase) with potential anticancer activity. |
|
V0663 | Defactinib (VS6063, PF04554878) | 1073154-85-4 | Defactinib (formerly known as VS-6063, PF-04554878) is a selective, ATP-competitive and orally bioactive small molecule inhibitor of the FAK (focal adhesion kinase) with potential antitumor activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
